Zilberberg, Marya D.
Harrington, Rachel
Spalding, James R.
Shorr, Andrew F.
Funding for this research was provided by:
Astellas Pharma Global Development, Inc., Northbrook, IL, US.
Article History
Received: 7 March 2018
Accepted: 1 May 2019
First Online: 17 May 2019
Authors’ information
: Rachel Harrington was affiliated to Astellas Pharma Global Development, Inc., Northbrook, IL, USA at the time of the study.
: The data used in this study are all de-identified and publicly available, obviating the requirement for an ethics committee evaluation.
: Not applicable
: MDZ reports grants from EviMed Research Group, LLC and Astellas Pharma Inc., during the conduct of the study, personal fees from Paratek, Tetraphase, Melinta, Achaogen, Pfizer, Shionogi, and Cleveland Clinic, grants from Merck and The Medicines Company, and stock ownership from Johnson & Johnson, outside the submitted work; RH was an employee of Astellas Pharma Global Development, Inc. at the time of study and is currently supported by NCI training grant 5R25-CA057699; JS is an employee of Astellas Pharma Global Development, Inc.; AFS has received consultancy fees, research support, and speaker honoraria from Astellas and Merck, and consultancy fees from Cidara.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.